Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2021.06.050
- Author:
Mei-Fang LAI
1
;
Fei LI
2
Author Information
1. Department of Hematology,The First Affiliated Hospital of Nanchang University, Institute of Hematology, Jiangxi Academy of Clinical Medical Sciences, Institute of Lymphatic Tumor Diseases of Nanchang University, Nanchang 330006,Jiangxi Province, China.
2. Department of Hematology,The First Affiliated Hospital of Nanchang University, Institute of Hematology, Jiangxi Academy of Clinical Medical Sciences, Institute of Lymphatic Tumor Diseases of Nanchang University, Nanchang 330006,Jiangxi Province, China.E-mail: yx021021@sina.com.
- Publication Type:Review
- MeSH:
Antineoplastic Agents;
Humans;
Immunophenotyping;
Leukemia, Prolymphocytic, T-Cell/genetics*;
Protein Kinase Inhibitors
- From:
Journal of Experimental Hematology
2021;29(6):1977-1981
- CountryChina
- Language:Chinese
-
Abstract:
T-cell prolymphocytic leukemia (T-PLL) is a rare but highly aggressive and malignant mature T-lymphoid tumor. The diagnosis of T-PLL mainly depend on genetic characteristics, clinical manifestations, cell morphology and immunophenotype. At present, clinical treatment is mainly aimed at improving the response rate and prolonging the remission period. With the development of new molecular biology technologies, researchers have gained a deeper understanding of the pathogenesis and related genetics of T-PLL, targeted drugs, including HDAC inhibitors, JAK/STAT inhibitors, AKT inhibitors and BCL-2 inhibitors, are also under evolution and providing the new opportunities to improve the efficacy of therapy. In this review, the advances in genetics and treatment of T-PLL were summarized briefly.
